Abstract
Objective: To investigate the clinical effect of irbesartan combined with potassium magnesium aspartate (PMA) in the treatment of rheumatic heart disease. Methods: A total of 316 patients with rheumatic heart disease who were treated in our hospital during the period of March 2018 to January 2021 were selected as the research objects. According to the different treatment methods, they were divided into group A (treatment with irbesartan only) and group B (Using Irbesartan combined with PMA treatment), analyze and compare the cardiac function, diastolic blood pressure, systolic blood pressure, heart rate and clinical treatment effect of the two groups of patients after treatment. Results: After treatment, the left ventricular end-systolic diameter (LVESD), left atrial diameter (LAD), and left ventricular end-diastolic diameter (LVEDD) of the two groups were significantly lower than before treatment, and left ventricular ejection fraction (LVEF) was significantly higher than after treatment, (P<0.05), and the improvement of the above indicators in group B was significantly better than that of group A, (P<0.05). After treatment, the diastolic blood pressure, systolic blood pressure and heart rate of group B were significantly lower than those of group A, (P?0.05); the total effective rate of treatment in group B (87.4%) was higher than that of group A (76.3%), (P?0.05). Conclusion: Irbesartan combined with PMA in the treatment of rheumatic heart disease has a better clinical effect than irbesartan alone. It can promote the reconstruction of ventricular function, improve the clinical symptoms of patients, prevent heart failure, and can effectively promote the recovery of cardiac function in patients.